-
Mashup Score: 1
Results from the NIVOPOSTOP trial found improved DFS with adjuvant nivolumab plus cisplatin and RT for patients with LA-SCCHN.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet
Results from the NIVOPOSTOP trial found improved DFS with adjuvant nivolumab plus cisplatin and RT for patients with LA-SCCHN.
“Post-operative nivolumab added to SOC cisplatin-[radiotherapy] improved patient outcomes for resected high-risk LA-SCCHN, which could be proposed as a new standard treatment,” said Jean Bourhis, MD, PhD. #hncsm #ASCO25 | @ASCO https://t.co/tc2iL41nkj